Quantcast

Latest Coagulation system Stories

2014-04-02 15:37:00

Discovery could lead to more effective therapies to prevent heart attacks Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis. Scientists at Case Western Reserve School of Medicine and University Hospitals Case Medical Center have reached a...

2014-03-31 12:28:26

New Italian data uncover specific association between diet and blood cell markers of heart attack- and stroke-associated inflammation WASHINGTON, March 31, 2014 /PRNewswire-USNewswire/ -- New research further illuminates the heart-healthy benefits of the Mediterranean diet, tying the eating plan to lower levels of platelets and white blood cells, two markers of inflammation. Inflammation has an association with greater risk of heart attack and stroke. Study results are published...

2014-03-24 12:25:01

KING OF PRUSSIA, Pa., March 24, 2014 /PRNewswire/ -- Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical disorders such as hemophilia and von Willebrand disease are concerned. CSL Behring is awarding a Local Empowerment for Advocacy Development (LEAD) grant to help bleeding disorder patients develop a clearer understanding of ACA and potential areas of concern....

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-02-25 14:19:07

New approach could help doctors and surgeons diagnose blood coagulation status in near real time, significantly improving patient care Defective blood coagulation is one of the leading causes of preventable death in patients who have suffered trauma or undergone surgery. The body’s natural defense against severe blood loss is the clotting process, in which platelets, plasma proteins, and other blood components interact to form a sticky, mesh-like structure. But often things go wrong, and...

2014-02-20 08:30:34

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...

2014-02-11 12:27:14

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/h477tv/coagulation ) has announced the addition of the "Concise Analysis on the International Coagulation Self-Testing Devices, Markets, Players and Prospects" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ability of patients to self-monitor is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease...

2014-02-04 20:22:49

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis of the International New Oral Anticoagulants Markets" [http://www.researchandmarkets.com/research/vgwhc9/new_oral ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Anticoagulants decrease the ability of the blood to create harmful blood clots that can...

2014-02-04 20:22:36

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxcwmp/coagulation) has announced the addition of the "Concise Analysis of the International Coagulation Diagnostic Testing Markets" [http://www.researchandmarkets.com/research/qxcwmp/coagulation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Coagulation testing, which encompasses both laboratory and point of care...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related